Wall Street analysts expect Cerulean Pharma Inc. (NASDAQ:CERU) to post earnings of ($0.34) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Cerulean Pharma’s earnings. Cerulean Pharma posted earnings per share of ($0.40) during the same quarter last year, which would indicate a positive year over year growth rate of 15%. The business is expected to issue its next quarterly earnings results on Thursday, August 3rd.

On average, analysts expect that Cerulean Pharma will report full-year earnings of ($1.42) per share for the current financial year. For the next fiscal year, analysts expect that the business will post earnings of ($1.43) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Cerulean Pharma.

WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/27/0-34-earnings-per-share-expected-for-cerulean-pharma-inc-ceru-this-quarter.html.

An institutional investor recently raised its position in Cerulean Pharma stock. Vanguard Group Inc. increased its stake in Cerulean Pharma Inc. (NASDAQ:CERU) by 79.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 899,398 shares of the biotechnology company’s stock after buying an additional 397,790 shares during the period. Vanguard Group Inc. owned about 3.10% of Cerulean Pharma worth $731,000 as of its most recent filing with the SEC. Institutional investors own 21.70% of the company’s stock.

Cerulean Pharma (NASDAQ CERU) traded down 2.076% during midday trading on Tuesday, reaching $0.415. 311,720 shares of the company’s stock were exchanged. The company’s market cap is $12.04 million. Cerulean Pharma has a 52 week low of $0.32 and a 52 week high of $3.58. The firm has a 50-day moving average price of $0.41 and a 200 day moving average price of $0.86.

Cerulean Pharma Company Profile

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

Get a free copy of the Zacks research report on Cerulean Pharma (CERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.